Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    51,086.62
    -540.31 (-1.05%)
     

  • CMC Crypto 200

    1,327.34
    -69.20 (-4.96%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Chemed (CHE) Stock Sinks As Market Gains: What You Should Know

Zacks Equity Research
·3-min read

Chemed (CHE) closed at $478.51 in the latest trading session, marking a -0.78% move from the prior day. This change lagged the S&P 500's daily gain of 0.48%. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq added 1.29%.

CHE will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $3.79, up 12.8% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $509.33 million, up 7.55% from the year-ago period.

CHE's full-year Zacks Consensus Estimates are calling for earnings of $16.43 per share and revenue of $2.11 billion. These results would represent year-over-year changes of +17.78% and +8.78%, respectively.

Any recent changes to analyst estimates for CHE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.

ADVERTISEMENT

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.15% lower. CHE is currently a Zacks Rank #3 (Hold).

Valuation is also important, so investors should note that CHE has a Forward P/E ratio of 29.35 right now. This represents a discount compared to its industry's average Forward P/E of 29.64.

Investors should also note that CHE has a PEG ratio of 2.99 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Medical - Outpatient and Home Healthcare stocks are, on average, holding a PEG ratio of 2.98 based on yesterday's closing prices.

The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 34% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Chemed Corporation (CHE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research